Treatment of relapsed acute leukemia by Ara C plus donor lymphocyte infusion using CD34+ cells reserved at the time of allogeneic transplantation
Abstract:Currently, there is no standard therapy available for relapsed acute leukemia after allogeneic hematopoietic cell transplantation(allo-HCT) . In this study, we evaluated the efficacy of cytoreduction with cytarabine followed by granulocyte colony-stimulating factor(G-CSF) -primed donor lymphocyte infusion(DLI)for patients with acute leukemia who relapsed after allo-HCT. We retrospectively reviewed 255 patients who had received allo-HCT for acute leukemia/myelodysplastic syndrome. Patients were divided into two… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.